Articles tagged with: Maintenance Therapy


[ by | Aug 20, 2012 11:36 am | Comments Off ]
Donor Stem Cell Transplantation Plus Revlimid Maintenance May Be Effective For Relapsed / Refractory Multiple Myeloma

Results of a recent, small German study show that donor stem cell trans­plan­tation followed by Revlimid maintenance therapy may be feasible in heavily pretreated relapsed or refractory multiple myeloma patients.

“For younger and fit patients, [donor] stem cell transplantation followed by maintenance therapy with [Revlimid] is a reasonable treatment option for patients who have already relapsed [after an autologous stem cell transplant],” said Dr. Nicolaus Kröger of the University Hospital Hamburg-Eppendorf in Germany and lead investigator of the study.

Dr. Philip McCarthy of the Roswell Park Cancer Institute in Buffalo, …

Read the full story »


[ by | Aug 2, 2012 10:48 am | 38 Comments ]
Pat’s Place: What a Wonderful Word – Remission!

Monday was a big day for me.

After undergoing 36 consecutive weeks of Revlimid, Velcade, and dexamethasone therapy since my stem cell transplant, I was hoping that Monday would be the day I could officially begin my easier-to-tolerate maintenance regimen.

Combination therapy with Revlimid (lenalidomide), Velcade (bortezomib), and dexamethasone (Decadron), known as RVD, had been tough for me to take over the last few months.  My platelet and white blood cell counts had been low and continued to edge down.  I was sore and out-of-sorts.  My body …

Read the full story »


[ by | Jul 27, 2012 11:32 am | 12 Comments ]
Maintenance Therapy For Multiple Myeloma (ASCO 2012)

Dr. Michel Attal from the Purpan Hospital in Toulouse, France, presented a review of current maintenance therapies for multiple myeloma during the American Society of Clinical Oncology (ASCO) annual meeting last month.

The focus of Dr. Attal’s presentation was on whether there is evidence to support the use of the novel anti-myeloma agents thalidomide (Thalo­mid), Revlimid (lenalidomide), and Velcade (bortezomib) as mainte­nance therapy after initial therapy and stem cell transplantation.

Maintenance therapy refers to a prolonged, and often low-dose, form of treatment given to myeloma patients after …

Read the full story »

News, Opinion»

[ by | Jul 13, 2012 11:43 am | 15 Comments ]
To Maintain Or Not To Maintain – That Is The Question!

Currently, there are three major controversies in multiple myeloma patient management: early versus late transplant, treat or observe ‘high-risk’ smoldering myeloma, and whether to use maintenance therapy. The latter is predominantly an issue following autologous stem cell transplantation.

In May, one of the world’s premier medical journals, the New England Journal of Medicine, published three articles about clinical trials comparing Revlimid (lenalidomide) maintenance versus observation.  In two of the studies, Revlimid maintenance was given following autologous stem cell transplantation.  In the third study, Revlimid maintenance was given following conventional …

Read the full story »


[ by | Jun 5, 2012 3:50 pm | Comments Off ]
ASCO 2012 Multiple Myeloma Update – Day Four: Poster Presentations On Current Myeloma Treatments

Today concludes this year’s American Society of Clinical Oncology (ASCO) annual meeting, which began on Friday in Chicago.  However, yesterday was the last day with any multiple myeloma-related sessions.

During yesterday’s poster session, important new research findings were summarized on posters throughout a large conference hall.

The studies were on a wide variety of myeloma-related topics ranging from new treatments being developed for myeloma, to currently used regimens, to secondary cancers, to precursor myeloma diseases, and much more.

This update covers some of the myeloma-related studies presented during the poster …

Read the full story »